These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20676126)

  • 1. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.
    Munro AF; Cameron DA; Bartlett JM
    Oncogene; 2010 Sep; 29(38):5231-40. PubMed ID: 20676126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for anthracycline-based chemotherapy for human breast cancer.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kono S; Morimoto K; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer; 2010 Apr; 17(2):103-9. PubMed ID: 19657712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 and topoisomerase II as predictors of response to chemotherapy.
    Pritchard KI; Messersmith H; Elavathil L; Trudeau M; O'Malley F; Dhesy-Thind B
    J Clin Oncol; 2008 Feb; 26(5):736-44. PubMed ID: 18258981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
    Gennari A; Pronzato P
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting anthracycline benefit: have we made any progress?
    Moretti E; Oakman C; Di Leo A
    Curr Opin Oncol; 2009 Nov; 21(6):507-15. PubMed ID: 19713842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
    Pritchard KI; Munro A; O'Malley FP; Tu D; Li X; Levine MN; Shepherd L; Chia S; Bartlett JM
    Breast Cancer Res Treat; 2012 Jan; 131(2):541-51. PubMed ID: 22042366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
    Glynn RW; Miller N; Whelan MC; Kerin MJ
    Ann Surg Oncol; 2010 May; 17(5):1392-7. PubMed ID: 20217261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
    Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I
    Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.